Keyphrases
Nonalcoholic Steatohepatitis
100%
Placebo-controlled
100%
Randomized Double-blind
100%
Aramchol
100%
Confidence Interval
50%
Placebo
50%
Fibrosis
50%
Stearoyl-CoA Desaturase 1 (SCD1)
37%
Odds Ratio
25%
Alanine Aminotransferase
25%
Liver Histology
25%
Hepatocellular Carcinoma
12%
Rodents
12%
Adverse Events
12%
Statistical Analysis
12%
Serious Adverse Events
12%
Cirrhosis
12%
Steatohepatitis
12%
Steatosis
12%
Insulin Resistance
12%
Magnetic Resonance Spectroscopy
12%
Chronic Liver Disease
12%
Early Termination
12%
1-stage
12%
Promising Treatment
12%
Early Phase Clinical Trials
12%
Liver Enzymes
12%
Severe Adverse Events
12%
Liver Lipid
12%
Hepatic Fat
12%
Partial Inhibition
12%
Liver Fat
12%
Lipotoxicity
12%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Placebo
100%
Fibrosis
66%
Arm
50%
Adverse Event
33%
Triacylglycerol
33%
Odds Ratio
33%
Alanine Aminotransferase
33%
Liver Histology
33%
Hepatocellular Carcinoma
16%
Clinical Trial
16%
Liver Cirrhosis
16%
Nuclear Magnetic Resonance Spectroscopy
16%
Insulin Resistance
16%
Chronic Liver Disease
16%
Steatosis
16%
Fatty Liver
16%
Liver Enzyme
16%
Steatohepatitis
16%
Lipotoxicity
16%
Acyl Coenzyme A Desaturase
16%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Nonalcoholic Fatty Liver
100%
Fibrosis
66%
Triacylglycerol
33%
Adverse Event
33%
Alanine Aminotransferase
33%
Liver Cell Carcinoma
16%
Liver Cirrhosis
16%
Steatosis
16%
Clinical Trial
16%
Insulin Resistance
16%
Chronic Liver Disease
16%
Fatty Liver
16%
Acyl Coenzyme A Desaturase
16%
Lipotoxicity
16%